` TSVT (2Seventy Bio Inc) vs S&P 500 Comparison - Alpha Spread

TSVT
vs
S&P 500

Over the past 12 months, TSVT has significantly outperformed S&P 500, delivering a return of 34% compared to the S&P 500's 9% growth.

Stocks Performance
TSVT vs S&P 500

Loading
TSVT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TSVT vs S&P 500

Performance Gap Between TSVT and GSPC
HIDDEN
Show

Performance By Year
TSVT vs S&P 500

Loading
TSVT
S&P 500
Add Stock

Competitors Performance
2Seventy Bio Inc vs Peers

S&P 500
TSVT
ABBV
AMGN
GILD
VRTX
Add Stock

2Seventy Bio Inc
Glance View

Market Cap
257.9m USD
Industry
Biotechnology

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.

TSVT Intrinsic Value
HIDDEN
Show
Back to Top